Repurposing of Rutan showed effective treatment for COVID-19 disease

Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 10; p. 1310129
Main Authors Salikhov, Shavkat I, Abdurakhmonov, Ibrokhim Y, Oshchepkova, Yuliya I, Ziyavitdinov, Jamolitdin F, Berdiev, Nodir Sh, Aisa, Haji Akber, Shen, Jingshan, Xu, Yechun, Xu, H Eric, Jiang, Xiangrui, Zhang, Leike, Vypova, Natalia L, Allaberganov, Dilshod Sh, Tagayalieva, Nigora A, Musabaev, Erkin I, Ibadova, Gulnara A, Rajabov, Ilxom B, Lokteva, Lyubov M
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 29.11.2023
Subjects
3CLpro
COVID-19
Medicine
RdRp
Rhus coriaria
Rutan
SARS-CoV-2
COVID-19
clinical trial
Rhus coriaria
SARS-CoV-2
Rutan
RdRp
3CLpro
Online AccessGet full text

Cover

Abstract Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children. ClinicalTrials.gov, ID NCT05862883.
AbstractList Previously, from the tannic sumac plant ( Rhus coriaria ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals’ organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children.
Previously, from the tannic sumac plant (Rhus coriaria), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children.Clinical Trial RegistrationClinicalTrials.gov, ID NCT05862883.
Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses, adenoviruses, paramyxoviruses, herpes virus, and cytomegalovirus. Here, our re-purposing study demonstrated that Rutan at 25, 50, and 100 mg/kg provided a very effective and safe treatment for COVID-19 infection, simultaneously inhibiting two vital enzyme systems of the SARS-CoV-2 virus: 3C-like proteinase (3CLpro) and RNA-dependent RNA polymerase (RdRp). There was no drug accumulation in experimental animals' organs and tissues. A clinical study demonstrated a statistically significant decrease in the C-reactive protein and a reduction of the viremia period. In patients receiving Rutan 25 mg (children) and 100 mg (adults), the frequency of post-COVID-19 manifestations was significantly less than in the control groups not treated with Rutan tablets. Rutan, having antiviral activity, can provide safe treatment and prevention of COVID-19 in adults and children. ClinicalTrials.gov, ID NCT05862883.
Author Xu, Yechun
Jiang, Xiangrui
Aisa, Haji Akber
Berdiev, Nodir Sh
Shen, Jingshan
Vypova, Natalia L
Allaberganov, Dilshod Sh
Salikhov, Shavkat I
Musabaev, Erkin I
Ziyavitdinov, Jamolitdin F
Lokteva, Lyubov M
Xu, H Eric
Ibadova, Gulnara A
Abdurakhmonov, Ibrokhim Y
Zhang, Leike
Rajabov, Ilxom B
Oshchepkova, Yuliya I
Tagayalieva, Nigora A
AuthorAffiliation 5 Wuhan Institute of Virology, Chinese Academy of Sciences , Wuhan , China
7 Centre for the Development of Professional Qualification of Medical Workers , Tashkent , Uzbekistan
4 State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai , China
6 Scientific-Research Institute of Virology of the Ministry of the Health of Uzbekistan , Tashkent , Uzbekistan
3 Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Ürümqi , China
2 Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan , Tashkent , Uzbekistan
1 A.S. Sadykov Institute of Bioorganic Chemistry (UzAS) , Tashkent , Uzbekistan
AuthorAffiliation_xml – name: 2 Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan , Tashkent , Uzbekistan
– name: 5 Wuhan Institute of Virology, Chinese Academy of Sciences , Wuhan , China
– name: 6 Scientific-Research Institute of Virology of the Ministry of the Health of Uzbekistan , Tashkent , Uzbekistan
– name: 7 Centre for the Development of Professional Qualification of Medical Workers , Tashkent , Uzbekistan
– name: 1 A.S. Sadykov Institute of Bioorganic Chemistry (UzAS) , Tashkent , Uzbekistan
– name: 4 State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai , China
– name: 3 Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences , Ürümqi , China
Author_xml – sequence: 1
  givenname: Shavkat I
  surname: Salikhov
  fullname: Salikhov, Shavkat I
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 2
  givenname: Ibrokhim Y
  surname: Abdurakhmonov
  fullname: Abdurakhmonov, Ibrokhim Y
  organization: Center of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan
– sequence: 3
  givenname: Yuliya I
  surname: Oshchepkova
  fullname: Oshchepkova, Yuliya I
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 4
  givenname: Jamolitdin F
  surname: Ziyavitdinov
  fullname: Ziyavitdinov, Jamolitdin F
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 5
  givenname: Nodir Sh
  surname: Berdiev
  fullname: Berdiev, Nodir Sh
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 6
  givenname: Haji Akber
  surname: Aisa
  fullname: Aisa, Haji Akber
  organization: Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Ürümqi, China
– sequence: 7
  givenname: Jingshan
  surname: Shen
  fullname: Shen, Jingshan
  organization: State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
– sequence: 8
  givenname: Yechun
  surname: Xu
  fullname: Xu, Yechun
  organization: State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
– sequence: 9
  givenname: H Eric
  surname: Xu
  fullname: Xu, H Eric
  organization: State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
– sequence: 10
  givenname: Xiangrui
  surname: Jiang
  fullname: Jiang, Xiangrui
  organization: State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
– sequence: 11
  givenname: Leike
  surname: Zhang
  fullname: Zhang, Leike
  organization: Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
– sequence: 12
  givenname: Natalia L
  surname: Vypova
  fullname: Vypova, Natalia L
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 13
  givenname: Dilshod Sh
  surname: Allaberganov
  fullname: Allaberganov, Dilshod Sh
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 14
  givenname: Nigora A
  surname: Tagayalieva
  fullname: Tagayalieva, Nigora A
  organization: A.S. Sadykov Institute of Bioorganic Chemistry (UzAS), Tashkent, Uzbekistan
– sequence: 15
  givenname: Erkin I
  surname: Musabaev
  fullname: Musabaev, Erkin I
  organization: Scientific-Research Institute of Virology of the Ministry of the Health of Uzbekistan, Tashkent, Uzbekistan
– sequence: 16
  givenname: Gulnara A
  surname: Ibadova
  fullname: Ibadova, Gulnara A
  organization: Centre for the Development of Professional Qualification of Medical Workers, Tashkent, Uzbekistan
– sequence: 17
  givenname: Ilxom B
  surname: Rajabov
  fullname: Rajabov, Ilxom B
  organization: Centre for the Development of Professional Qualification of Medical Workers, Tashkent, Uzbekistan
– sequence: 18
  givenname: Lyubov M
  surname: Lokteva
  fullname: Lokteva, Lyubov M
  organization: Scientific-Research Institute of Virology of the Ministry of the Health of Uzbekistan, Tashkent, Uzbekistan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38093975$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1PGzEQQK0qqAmUH9BLtcdeNvX4Y9c-VVVoSyQkJASoN8uxx2HRZp3au1T8ezYkjeDkkT3zZsbvlEy62CEhn4HOOVf6W9ignzPK-Bw4UGD6A5kxpqtSSfVn8iaekvOcHymlwJkUwD-SKVdUc13LGbm4we2QtjE33bqIobgZetsV-SH-Q19gCOj65gmLPqHtN9j1RYipWFzfLy9K0IVvMtqMn8hJsG3G88N5Ru5-_bxdXJZX17-Xix9XpROg-lJbC16CCt4KKr0Hy1klcCVQoaYASlEvQFZOOF_VDmrJg-fjHr7SmoPmZ2S55_poH802NRubnk20jXm9iGltbOob16JRPqyqyrEgqBDaKauEcl5prAFXHuTI-r5nbYfV-JNu3C3Z9h30_UvXPJh1fDJAa6jGuUfC1wMhxb8D5t5smuywbW2HcciGacq0ZPK1GexTXYo5JwzHPkDNzqbZ2TQ7m-Zgc6z58nbAY8V_d_wFDKmcnw
Cites_doi 10.1016/j.jep.2014.08.031
10.1016/j.foodchem.2021.131594
10.1186/s12985-023-01968-6
10.1101/2020.11.01.363812
10.1038/s41586-020-2223-y
10.1073/pnas.2021579118
10.1016/S2055-6640(20)30016-9
10.1371/journal.pbio.0030324
10.1126/science.abc1560
10.1056/NEJMoa2007016
10.1186/s12941-020-00362-2
10.1038/s41467-021-25796-w
10.1021/acs.jcim.0c00821
10.7554/eLife.70968
10.1016/j.biopha.2021.111544
10.1099/0022-1317-81-4-853
10.1177/2040206620984076
10.1007/s12519-020-00343-7
10.3390/v13101981
10.1080/07391102.2020.1779818
10.3390/v14071458
10.1177/2472555220942123
10.1080/14756366.2021.1873977
10.1080/13543776.2021.1861248
10.3390/v13102060
10.3390/v10020076
10.3389/fpubh.2020.00216
10.1016/j.ijid.2020
10.21037/atm-20-3302
10.1056/NEJMoa2118542
10.1038/s41579-020-00468-6
10.1126/science.adf2350
10.1038/s41598-021-95565-8
10.1136/bmj.c332
10.3390/v11100961
ContentType Journal Article
Copyright Copyright © 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva.
Copyright © 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva. 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva
Copyright_xml – notice: Copyright © 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva.
– notice: Copyright © 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva. 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fmed.2023.1310129
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
CrossRef
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2296-858X
EndPage 1310129
ExternalDocumentID oai_doaj_org_article_8dfb66c2f40449c8a848cd89e71ebd15
10_3389_fmed_2023_1310129
38093975
Genre Journal Article
GrantInformation_xml – fundername: Ministry of the Innovative Development Republic of Uzbekistan
  grantid: I-FA-2021-72
GroupedDBID 53G
5VS
9T4
AAFWJ
ACGFS
ACXDI
ADBBV
ADRAZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
GROUPED_DOAJ
HYE
IAO
IEA
IHR
IHW
IPNFZ
ISR
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RPM
AAYXX
CITATION
7X8
5PM
AFPKN
ID FETCH-LOGICAL-c418t-9aa1d518fda405dd1a3264eb4e8e9011880d4156c4cd67c1753fd3229d6993193
IEDL.DBID RPM
ISSN 2296-858X
IngestDate Tue Oct 22 15:16:19 EDT 2024
Tue Sep 17 21:29:17 EDT 2024
Fri Oct 25 02:56:58 EDT 2024
Fri Nov 22 01:03:43 EST 2024
Sat Nov 02 12:05:02 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
clinical trial
Rhus coriaria
SARS-CoV-2
Rutan
RdRp
3CLpro
Language English
License Copyright © 2023 Salikhov, Abdurakhmonov, Oshchepkova, Ziyavitdinov, Berdiev, Aisa, Shen, Xu, Xu, Jiang, Zhang, Vypova, Allaberganov, Tagayalieva, Musabaev, Ibadova, Rajabov and Lokteva.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c418t-9aa1d518fda405dd1a3264eb4e8e9011880d4156c4cd67c1753fd3229d6993193
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Shi Xue Dai, Guangdong Provincial People’s Hospital, China; Zhonglei Wang, Qufu Normal University, China
Edited by: Liyan Yang, Qufu Normal University, China
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10716264/
PMID 38093975
PQID 2902952515
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_8dfb66c2f40449c8a848cd89e71ebd15
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10716264
proquest_miscellaneous_2902952515
crossref_primary_10_3389_fmed_2023_1310129
pubmed_primary_38093975
PublicationCentury 2000
PublicationDate 2023-11-29
PublicationDateYYYYMMDD 2023-11-29
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-29
  day: 29
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in medicine
PublicationTitleAlternate Front Med (Lausanne)
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Yin (ref23) 2020
(ref28) 2001
Jin (ref36) 2020; 582
Majerová (ref8) 2021; 13
Ziyavitdinov (ref21) 2020; 1
Bahun (ref40) 2022; 373
Keni (ref1) 2020; 8
Yang (ref10) 2005; 3
Leslie (ref2) 2022; 378
Chaves (ref34) 2022; 14
Xu (ref7) 2020; 60
(ref24) 2018
Ballou (ref41) 1992; 37
Ghosh (ref12) 2021; 39
Venkataraman (ref13) 2018; 10
(ref26) 2011
Lopez-Leon (ref18) 2021; 11
Pilkington (ref33) 2020; 6
Liu (ref37) 2021; 36
Meyer (ref6) 2021; 12
Jan (ref39) 2021; 118
Ziebuhr (ref3) 2000; 81
(ref29) 2000
Nelemans (ref5) 2019; 11
Seifert (ref16) 2021
Shen (ref44) 2020; 16
Mironov (ref25) 2012
Molavi (ref17) 2021; 138
Cusinato (ref20) 2021; 31
Li (ref38) 2014; 156
Chen (ref42) 2020; 19
Wu (ref9) 2023; 20
Zhang (ref4) 2021; 13
V’kovski (ref15) 2021; 19
Grein (ref35) 2020; 382
Wang (ref43) 2020; 8
Zhu (ref14) 2020; 25
Ogunyemi (ref31) 2020; 28
Hammond (ref11) 2022; 386
Schulz (ref30) 2010; 2010
Udwadia (ref32) 2021; 103
Salikhov (ref19) 2012
Yin (ref22) 2020; 368
(ref27) 2010
References_xml – year: 2011
  ident: ref26
  article-title: Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use, ICH guidelines S2(R1)
– volume: 156
  start-page: 210
  year: 2014
  ident: ref38
  article-title: Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2014.08.031
  contributor:
    fullname: Li
– year: 2018
  ident: ref24
  article-title: On approval of the regulation on the procedure for state registration of medicines, medical devices and medical equipment and the issuance of a registration certificate
– volume: 373
  start-page: 131594
  year: 2022
  ident: ref40
  article-title: Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols
  publication-title: Food Chem
  doi: 10.1016/j.foodchem.2021.131594
  contributor:
    fullname: Bahun
– volume: 20
  start-page: 6
  year: 2023
  ident: ref9
  article-title: The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics
  publication-title: Virol J
  doi: 10.1186/s12985-023-01968-6
  contributor:
    fullname: Wu
– start-page: 39
  volume-title: OECD environmental health and safety publications series on testing and assessment ENV/JM/MONO
  year: 2000
  ident: ref29
  article-title: Guidance document on the recognition, Assessment, and use of clinical signs as humane endpoints for experimental animals used in safety evaluation
– year: 2020
  ident: ref23
  article-title: Structural basis for repurpose and design of nucleoside drugs for treating COVID-19
  doi: 10.1101/2020.11.01.363812
  contributor:
    fullname: Yin
– volume: 582
  start-page: 289
  year: 2020
  ident: ref36
  article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
  publication-title: Nature
  doi: 10.1038/s41586-020-2223-y
  contributor:
    fullname: Jin
– volume: 118
  start-page: e2021579118
  year: 2021
  ident: ref39
  article-title: Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2021579118
  contributor:
    fullname: Jan
– volume: 37
  start-page: 313
  year: 1992
  ident: ref41
  article-title: C-reactive protein and the acute phase response
  publication-title: Adv Intern Med
  contributor:
    fullname: Ballou
– start-page: 944
  volume-title: Guidelines for conducting preclinical studies of drugs
  year: 2012
  ident: ref25
  contributor:
    fullname: Mironov
– volume-title: Test No. 420: acute oral toxicity—fixed dose procedure, OECD guidelines for the testing of chemicals
  year: 2001
  ident: ref28
– volume: 6
  start-page: 45
  year: 2020
  ident: ref33
  article-title: A review of the safety of favipiravir—a potential treatment in the COVID-19 pandemic?
  publication-title: J Virus Erad
  doi: 10.1016/S2055-6640(20)30016-9
  contributor:
    fullname: Pilkington
– volume: 3
  start-page: e324
  year: 2005
  ident: ref10
  article-title: Design of wide-spectrum inhibitors targeting coronavirus main proteases
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.0030324
  contributor:
    fullname: Yang
– volume: 368
  start-page: 1499
  year: 2020
  ident: ref22
  article-title: Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
  publication-title: Science
  doi: 10.1126/science.abc1560
  contributor:
    fullname: Yin
– volume: 382
  start-page: 2327
  year: 2020
  ident: ref35
  article-title: Compassionate use of Remdesivir for patients with severe COVID-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2007016
  contributor:
    fullname: Grein
– volume-title: The Agency on the Intellectual Property Republic of Uzbekistan
  year: 2012
  ident: ref19
  article-title: An anti-influenza agent
  contributor:
    fullname: Salikhov
– volume: 19
  start-page: 18
  year: 2020
  ident: ref42
  article-title: Plasma CRP level is positively associated with the severity of COVID-19
  publication-title: Ann Clin Microbiol Antimicrob
  doi: 10.1186/s12941-020-00362-2
  contributor:
    fullname: Chen
– volume: 12
  start-page: 5553
  year: 2021
  ident: ref6
  article-title: Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-25796-w
  contributor:
    fullname: Meyer
– volume: 60
  start-page: 5735
  year: 2020
  ident: ref7
  article-title: Systemic in silico screening in drug discovery for coronavirus disease (COVID-19) with an online interactive web server
  publication-title: J Chem Inf Model
  doi: 10.1021/acs.jcim.0c00821
  contributor:
    fullname: Xu
– year: 2021
  ident: ref16
  article-title: Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single molecule perspective
  doi: 10.7554/eLife.70968
  contributor:
    fullname: Seifert
– volume: 138
  start-page: 111544
  year: 2021
  ident: ref17
  article-title: Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2021.111544
  contributor:
    fullname: Molavi
– volume: 81
  start-page: 853
  year: 2000
  ident: ref3
  article-title: Virus-encoded proteinases and proteolytic processing in the Nidovirales
  publication-title: J Gen Virol
  doi: 10.1099/0022-1317-81-4-853
  contributor:
    fullname: Ziebuhr
– volume: 28
  start-page: 2040206620984076
  year: 2020
  ident: ref31
  article-title: Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective
  publication-title: Antivir Chem Chemother
  doi: 10.1177/2040206620984076
  contributor:
    fullname: Ogunyemi
– volume: 16
  start-page: 223
  year: 2020
  ident: ref44
  article-title: Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement
  publication-title: World J Pediatr
  doi: 10.1007/s12519-020-00343-7
  contributor:
    fullname: Shen
– volume: 13
  start-page: 1981
  year: 2021
  ident: ref8
  article-title: Precursors of viral proteases as distinct drug targets
  publication-title: Viruses
  doi: 10.3390/v13101981
  contributor:
    fullname: Majerová
– volume: 39
  start-page: 4362
  year: 2021
  ident: ref12
  article-title: Evaluation of green tea polyphenols as novel coronavirus (SARS CoV-2) main protease (Mpro) inhibitors—an in silico docking and molecular dynamics simulation study
  publication-title: J Biomol Struct Dyn
  doi: 10.1080/07391102.2020.1779818
  contributor:
    fullname: Ghosh
– start-page: 33
  year: 2010
  ident: ref27
  article-title: Directive 2010/63/EU on the protection of animals used for scientific purposes
  publication-title: Off J Eur Union
– volume: 14
  start-page: 1458
  year: 2022
  ident: ref34
  article-title: Commercially available flavonols are better SARS-CoV-2 inhibitors than isoflavone and flavones
  publication-title: Viruses
  doi: 10.3390/v14071458
  contributor:
    fullname: Chaves
– volume: 25
  start-page: 1141
  year: 2020
  ident: ref14
  article-title: RNA-Dependent RNA polymerase as a target for COVID-19 drug discovery
  publication-title: SLAS Discov
  doi: 10.1177/2472555220942123
  contributor:
    fullname: Zhu
– volume: 36
  start-page: 497
  year: 2021
  ident: ref37
  article-title: Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro
  publication-title: J Enzyme Inhib Med Chem
  doi: 10.1080/14756366.2021.1873977
  contributor:
    fullname: Liu
– volume: 31
  start-page: 295
  year: 2021
  ident: ref20
  article-title: Repurposing drugs for the management of COVID-19
  publication-title: Expert Opin Ther Pat
  doi: 10.1080/13543776.2021.1861248
  contributor:
    fullname: Cusinato
– volume: 13
  start-page: 2060
  year: 2021
  ident: ref4
  article-title: An update on innate immune responses during SARS-CoV-2 infection
  publication-title: Viruses
  doi: 10.3390/v13102060
  contributor:
    fullname: Zhang
– volume: 10
  start-page: 76
  year: 2018
  ident: ref13
  article-title: RNA dependent RNA polymerases: insights from structure, function and evolution
  publication-title: Viruses
  doi: 10.3390/v10020076
  contributor:
    fullname: Venkataraman
– volume: 8
  start-page: 216
  year: 2020
  ident: ref1
  article-title: COVID-19: emergence, spread, possible treatments, and global burden
  publication-title: Front Public Health
  doi: 10.3389/fpubh.2020.00216
  contributor:
    fullname: Keni
– volume: 103
  start-page: 62
  year: 2021
  ident: ref32
  article-title: Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2020
  contributor:
    fullname: Udwadia
– volume: 8
  start-page: 620
  year: 2020
  ident: ref43
  article-title: Clinical characteristics of children with COVID-19: a rapid review and meta-analysis
  publication-title: Ann Transl Med
  doi: 10.21037/atm-20-3302
  contributor:
    fullname: Wang
– volume: 386
  start-page: 1397
  year: 2022
  ident: ref11
  article-title: Oral Nirmatrelvir for high-risk, nonhospitalized adults with COVID-19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2118542
  contributor:
    fullname: Hammond
– volume: 19
  start-page: 155
  year: 2021
  ident: ref15
  article-title: Coronavirus biology and replication: implications for SARS-CoV-2
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-020-00468-6
  contributor:
    fullname: V’kovski
– volume: 378
  start-page: 128
  year: 2022
  ident: ref2
  article-title: A viral arsenal
  publication-title: Science
  doi: 10.1126/science.adf2350
  contributor:
    fullname: Leslie
– volume: 11
  start-page: 16144
  year: 2021
  ident: ref18
  article-title: More than 50 long-term effects of COVID-19: a systematic review and meta-analysis
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-95565-8
  contributor:
    fullname: Lopez-Leon
– volume: 1
  start-page: 133
  year: 2020
  ident: ref21
  article-title: Structure of polyphenols of leaves tanning sumac Rhus coriaria l
  publication-title: Khimiya Rastit Syr
  contributor:
    fullname: Ziyavitdinov
– volume: 2010
  start-page: c332
  year: 2010
  ident: ref30
  article-title: CONSORT statement: updated guidelines for reporting parallel group randomised trials
  publication-title: BMJ
  doi: 10.1136/bmj.c332
  contributor:
    fullname: Schulz
– volume: 11
  start-page: 961
  year: 2019
  ident: ref5
  article-title: Viral innate immune evasion and the pathogenesis of emerging RNA virus infections
  publication-title: Viruses
  doi: 10.3390/v11100961
  contributor:
    fullname: Nelemans
SSID ssj0001325413
Score 2.2908876
Snippet Previously, from the tannic sumac plant ( ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B viruses,...
Previously, from the tannic sumac plant ( Rhus coriaria ), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B...
Previously, from the tannic sumac plant (Rhus coriaria), we developed the Rutan 25 mg oral drug tablets with antiviral activity against influenza A and B...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1310129
SubjectTerms 3CLpro
COVID-19
Medicine
RdRp
Rhus coriaria
Rutan
SARS-CoV-2
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS8MwFA6yg3gRfzt_EcGTUG2atEuOujmmMAVxsltIk5R5acVt-O_7XlPHJoIXr22g4Xtp3_f1vXwh5AJpuDMyx8NdZCR8nkUGVlYEmZmnPuHKWtycPHzMBiPxME7HS0d9YU9YsAcOwF1LV-RZZpNCxEIoK40U0jqpfIf53LHgXhonS2Kq_rvCQfgwHsqYoMIUhMmjMWjCrxhHTyu1kohqv_7fSObPXsml5NPfIpsNa6Q3YbbbZM2XO2R92NTFd0kPeDQgVqHwp1VBn-fA-eh0Un16R0PLBnzV6KKrnAJVpd2n1_texBRtijR7ZNS_e-kOouZ8hMgKJmeRMoa5lMnCGaBdzjEDXAzgFl76ekepjB3qMyusyzoWPTkLBy-wchmwEmBu-6RVVqU_JFRapXJQGjCQC27iXORpYS2kN-UTL7M2ufwGS78HGwwN8gGR1YisRmR1g2yb3CKci4HoYF1fgLjqJq76r7i2yfl3MDSseCxjmNJX86lOVJyoFHgZjDkIwVk8istYAcOCO3IlbCtzWb1Tvk1qV23QwQzUnTj6j9kfkw1EBDctJuqEtGYfc38K7GWWn9UL9Qt5oexg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-QLyIb9cXETwJlaZJa3IQ0dVFhVUQV7yFNEldQVrdB-q_d6btLq7syWuT0PJNpvNNZjJDyCHScGdkis1dZCB8mgQGdlYAlpnHPuLKWryc3L5Lrjvi9jl-niGj9lY1gP2prh32k-r03o6_Pr7PQOFP0eMEewsS8FjzM-LHjGO5KjVL5iMwjJjh1a7ZfnnkwsEbYryKbU5fOWGdyiL-05jn3wTKXxaptUyWaipJzyvZr5AZn6-ShXYdLF8jl0CuAcYCTwNokdGHIRBB2u8Wn97RKo8DfnV0nGpOgb_S5v3TzWXAFK0jN-uk07p6bF4HddOEwAomB4EyhrmYycwZ4GLOMQMEDWQgvPTlNVMZOnTarLAuObFYqDNzoNXKJUBVgM5tkLm8yP0WodIqlYL7ARO54CZMRRpn1oLNUz7yMmmQoxFY-r2qjaHBp0BkNSKrEVldI9sgFwjneCKWtS4fFL0XXWuJli5Lk8RGmQiFUFYaKaR1UvkT5lPH4gY5GAlDgxpgbMPkvhj2daTCSMVA1mDOZiWc8au4DBXQLhiRE2Kb-JbJkfy1W5baBueYgcsntv-_dIcsIg54fzFSu2Ru0Bv6PSAyg3S_3J4_z2nynw
  priority: 102
  providerName: Scholars Portal
Title Repurposing of Rutan showed effective treatment for COVID-19 disease
URI https://www.ncbi.nlm.nih.gov/pubmed/38093975
https://search.proquest.com/docview/2902952515
https://pubmed.ncbi.nlm.nih.gov/PMC10716264
https://doaj.org/article/8dfb66c2f40449c8a848cd89e71ebd15
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA7qQbyIb9cXETwJ3W2atCZHXRUVVkVc8RbyqrvgtqK7-PedpO2yK5689NCktHwz7XxfZzJB6MTTcKu49pu78Ig5nUUKPCuCyExTl1BhjF-c3LvPbvrs7jV9XUBZsxYmFO0bPWwX76N2MRyE2sqPkek0dWKdx14XJAsBIs46i2gR4u-MRg9_ViiIHkKrFCYoMAEmcr4paELbhPp-VmIuCIVe_X8RzN91kjOB53oNrdaMEZ9XT7aOFlyxgZZ7dU58E10Chwa0Si_6cZnjpwnwPfw1KL-dxVW5BnzR8LSiHANNxd2Hl9vLiAhcJ2i2UP_66rl7E9V7I0SGET6OhFLEpoTnVgHlspYo4GEANXPchdWkPLZemxlmbHZmfD_O3MLLK2wGjARY2zZaKsrC7SLMjRAaVAZMpIyqWDOd5sZAaBMucTxrodMGLPlRtcCQIB08stIjKz2yska2hS48nNOJvnt1OFF-vsnahpLbXGeZSXIWMyYMV5xxY7lwZ8RpS9IWOm6MIcHbfQpDFa6cfMlExIlIgZPBnJ3KONNbUR4LYFcwwufMNvcs8yPgYKGjduNQe_-_dB-teBz8MsVEHKCl8efEHQJfGeujoPPh2GP8KLjqD_c87LM
link.rule.ids 230,314,727,780,784,864,885,2102,24318,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9swFD5incR4QRsMKOxiJJ4mpY1jJ7UfWQGVjQJCMPFm-RZAggTRVvx9jnOp6MQTr7GjWN85ib8v52KAvUDDnRYmHO4iIu5NFmn0rAh3Zpb6hElrQ3Hy-DQbXfE_1-n1EmRtLUyVtG_NXa-4f-gVd7dVbuXjg-23eWL98_EQJQtFIs77H-BjygaSvlLp1b8VhrKHsjqIiRpMopF8aAuasB5loaOVXNiGqm79b1HM_zMlX209R59hteGMZL9e2xdY8sUaLI-bqPg6HCCLRrzKIPtJmZOLGTI-Mrktn70jdcIGftPIPKecIFElw7N_xwcRlaQJ0XyFq6PDy-Eoak5HiCynYhpJralLqcidRtLlHNXIxBBs7oWv6klF7II6s9y6bGBDR87c4esrXYacBHnbBnSKsvBbQISV0qDOwImMMx0bbtLcWtzcpE-8yLrwqwVLPdZNMBSKh4CsCsiqgKxqkO3C7wDnfGLoX11dKJ9uVGNFJVxusswmOY85l1ZowYV1QvoB9cbRtAu7rTEU-nsIYujCl7OJSmScyBRZGc7ZrI0zfxQTsUR-hSNiwWwLa1kcQReremq3LrX9_lt_wqfR5fhEnRyf_t2BlYBJKFpM5DfoTJ9m_juyl6n5UbnqC22g7jk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwELVYJMQFsVNWI3FCShvHTmofoaViKyAEiJvlLRQJkqqL-H3GSVpRxIlr7CjWm0nmvcx4jNCJp-FWce0Pd-EBczoJFHhWAJGZxi6iwhi_Obl7l1w-s-vX-LWqqhxWZZWZ0e_17OOznr33itrK_qdpTOrEGg_dFkgWAkScNfo2bcyjxZiCl_1Q6sX_FQrSh9AykQk6TIChnG8NGtE6ob6rlZgJRUXH_r9o5u9qyR_hp7OKVireiM_K9a2hOZeto6VulRnfQG1g0oBZ7qU_zlP8OAbWh4e9_MtZXBZtwHcNT-vKMZBV3Lp_uWoHROAqTbOJnjsXT63LoDohITCM8FEglCI2Jjy1CoiXtUQBGwPAmeOu2FPKQ-sVmmHGJk3ju3KmFl5hYRPgJcDdttBClmduB2FuhNCgNWAiZVSFmuk4NQYCnHCR40kNnU7Akv2yEYYEAeGRlR5Z6ZGVFbI1dO7hnE70PayLC_ngTVaWlNymOklMlLKQMWG44owby4VrEqctiWvoeGIMCT7vExkqc_l4KCMRRiIGZgZztkvjTB9FeSiAY8EInzHbzFpmR8DNir7aE7fa_f-tR2jpod2Rt1d3N3to2UPi9y1GYh8tjAZjdwAEZqQPC0_9Bt8B70w
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Repurposing+of+Rutan+showed+effective+treatment+for+COVID-19+disease&rft.jtitle=Frontiers+in+medicine&rft.au=Salikhov%2C+Shavkat+I.&rft.au=Abdurakhmonov%2C+Ibrokhim+Y.&rft.au=Oshchepkova%2C+Yuliya+I.&rft.au=Ziyavitdinov%2C+Jamolitdin+F.&rft.date=2023-11-29&rft.pub=Frontiers+Media+S.A&rft.eissn=2296-858X&rft.volume=10&rft_id=info:doi/10.3389%2Ffmed.2023.1310129&rft.externalDBID=PMC10716264
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon